Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
Summary
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION. Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administration (FDA) has said. Covered by 27 outlets: 10 lean left, 9 are centre, 3 lean right, 5 are not rated.
Automated summary picked from the outlets' own descriptions.
Who is covering this
-
GLP-1 drugs to carry warning about rare vision-loss side effect, FDA says
GLP-1 drugs will now carry a warning for a rare, but potentially dangerous side effect that can lead to vision loss, the FDA says. Dr. Rachel Pessah-Pollack joins CBS News to discuss.
-
FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead...
-
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
-
What to know about new GLP-1 warning on possible vision loss
Dr. Jon LaPook joins "CBS Mornings" to break down the facts on a new warning about GLP-1 medications causing possible vision loss.
-
GLP-1 Drugs Receive New Warning Labels Over Rare Blindness Risk
The order applies to all GLP-1s.
-
FDA adds rare vision-loss warning to popular obesity, diabetes drugs
The eye condition, known as non-arteritic anterior ischemic optic neuropathy, can cause significant vision loss and has been reported with all GLP-1 drugs,
-
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
-
"Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs
"Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs The FDA is requiring the makers of every GLP-1 drug on the U.S. market, Ozempic, Wegovy, Mounjaro and Zepbound among them, to warn of a potential increased risk of an "eye stroke" that can...
Low reliability sourceElevated risk -
GLP-1s must now include warning for potential increased risk of vision loss, FDA announces
The FDA announced that GLP-1 weight loss drugs will now include warning labels indicating a potential increased risk of vision loss.
-
FDA orders blindness risk warning on weight loss drugs
Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administration (FDA) has said.
-
FDA tells GLP-1 makers to warn of potential vision loss side effect - The Washington Post
FDA tells GLP-1 makers to warn of potential vision loss side effect The Washington Post US FDA orders new eye risk warnings for Ozempic, Zepbound CNN GLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect CBS News US is requiring weight-loss...
-
FDA warns of rare vision-loss side effect from GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
-
Do Ozempic, Zepbound cause vision loss? New FDA warning explained - USA Today
Do Ozempic, Zepbound cause vision loss? New FDA warning explained USA Today
-
FDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s
Health regulators have found a consistent link between GLP-1 use and the eye condition NAION.
-
FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs
The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior...
-
FDA adds rare vision-loss warning to popular GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic
-
GLP-1 drugs must have new warning label over incurable blindness condition, says FDA
You're going to want to keep an eye on this.
-
GLP-1 drugs to include new warning about rare eye condition causing sudden blindness, FDA says
The FDA is ordering drugmakers to add a new warning labels on GLP-1 injectables and pills linked to a rare eye condition that can cause sudden blindness.
-
GLP-1 drugs to include new warning about rare eye condition causing sudden blindness, FDA says
The FDA is ordering drugmakers to add a new warning labels on GLP-1 injectables and pills linked to a rare eye condition that can cause sudden blindness.
-
GLP-1 drugs to include new warning about rare eye condition causing sudden blindness, FDA says
The FDA is ordering drugmakers to add a new warning labels on GLP-1 injectables and pills linked to a rare eye condition that can cause sudden blindness.
-
FDA adds rare vision-loss warning to popular GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic.
-
FDA Requires GLP-1 Labels to Add Rare Eye Condition Risk
The FDA now requires information be added to the labels of GLP-1 receptor agonists about the potential increased risk for nonarteritic anterior ischemic optic neuropathy.
-
FDA says popular GLP-1 drugs linked to rare risk of vision loss, blindness - USA Today
FDA says popular GLP-1 drugs linked to rare risk of vision loss, blindness USA Today
-
FDA is requiring weight loss drug makers to add a vision loss warning
The warning covers all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a rare eye condition called NAION
-
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness - NBC News
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness NBC News US FDA orders new eye risk warnings for Ozempic, Zepbound CNN FDA warns GLP-1 drugs carry potential risk of rare eye condition STAT US regulator orders makers of weight-loss drugs to...
-
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness.
-
Ozempic Zepbound eye risk warnings: Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDA
Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (US FDA).
-
FDA Slaps New Safety Warning on GLP-1 Drugs
(MedPage Today) -- The FDA is requiring manufacturers of all GLP-1 drugs to update their prescribing information to include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding...
-
FDA orders warning in GLP-1 medicines: could cause vision loss
Translated FDA ordena advertencia en medicamentos GLP-1: podrían causar pérdida de visión
Video coverage
Related stories
Actor Ajay Devgn moves High Court against FDA notice over Vimal Elaichi ads
FDA scientists opposed Trump administration’s move to ease peptide access
Trump administration says biggest changes coming to infant formula in nearly 30 years
Blood pressure medication recalled nationwide
FDA issues alert about Northfield-based Medline beds tied to fire-related deaths and injuries
Comments
Comments need JavaScript.